(Q47918300)

6 February 2018

title

Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma (English)

1 reference

6 February 2018

author name string

S Zeynalova

1

1 reference

6 February 2018

M Ziepert

2

1 reference

6 February 2018

M Scholz

3

1 reference

6 February 2018

S Schirm

4

1 reference

6 February 2018

C Zwick

5

1 reference

6 February 2018

M Pfreundschuh

6

1 reference

6 February 2018

M Loeffler

7

1 reference

6 February 2018

German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

8

1 reference

6 February 2018

publication date

28 July 2013

1 reference

6 February 2018

published in

Annals of Hematology

1 reference

6 February 2018

volume

92

1 reference

6 February 2018

issue

12

1 reference

6 February 2018

page(s)

1641-1652

1 reference

6 February 2018

Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Initial empirical antibiotic therapy for neutropenic fever: analysis of the causes of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Severity of illness scores: are they useful in febrile neutropenic adult patients in hematology wards? A prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Modelling human granulopoiesis under poly-chemotherapy with G-CSF support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

The role of pegfilgrastim in mobilization of hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1842-X

10.1007/S00277-013-1842-X

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018